AbbVie to collaborate with Teneobio to develop TNB 383B for multiple myeloma.

AbbVie will partner with Teneobio and its affiliate TeneoOne, Inc., to develop and commercialize its lead program, the preclinical cancer immunotherapy candidate TNB-383B for multiple myeloma, through a collaboration that gives AbbVie the option to buy the startup.

B-cell maturation antigen (BCMA) has emerged as an attractive target for multiple myeloma therapeutics. TNB-383B is a bispecific antibody designed to simultaneously target B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3). TNB-383B is among Human Heavy Chain Antibodies (UniAbs) the company is developing for indications in cancer, autoimmunity, and infectious diseases, using its TeneoSeek antibody discovery engine, designed to rapidly identify large numbers of unique binding molecules specific for therapeutic targets of interest.